

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Zafirlukast
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zafirlukast is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2011
Lead Product(s) : Zafirlukast
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zafirlukast
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Quercis Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Western New England University and Quercis Pharma Sign Exclusive Worldwide License Agreements
Details : Zafirlukast (Accolate®) is in a class of medications known as leukotriene receptor antagonists (LTRAs) that work by blocking the action of certain natural substances that cause swelling and tightening of the airways.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 19, 2021
Lead Product(s) : Zafirlukast
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Quercis Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement




DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.